Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
African Forests Have Become a Source of Carbon Emissions - 2Find the Marvels of the World with These Travels
- 3The Most Rousing Ladies Business visionaries of Today
- 4Plane Passenger Allegedly Includes ‘Bomb Threat’ in Hotspot Network Name, Forces Flight to Make Emergency Landing
- 5Language Learning Applications for Voyagers
- Nurturing Hacks: Shrewdness from Experienced Mothers and Fathers
- Artemis 2 breaks humanity's all-time distance record during historic loop around the moon (video)
- What are parents to do as doctors clash with Trump administration over vaccines?
- Former 'Bachelorette' welcomes 1st baby via emergency c-section
- EU states agree first step for Ukraine reparations fund
- The most effective method to Comprehend the Variables Affecting Medical attendant Pay rates
- Do-It-Yourself Home Style on a Careful spending plan: Imaginative Thoughts and Tasks
- Virtual Domains d: A Survey of \Inundation and Ongoing interaction Mechanics\ Computer game
- Tire Brands for Senior Drivers: Guaranteeing Security and Solace
